"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.
about
Epigenetic control of HIV-1 post integration latency: implications for therapyThe macrophage: a therapeutic target in HIV-1 infectionNew developments in anti-malarial target candidate and product profilesActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyTherapy for persistent HIV.Eradication therapies for HIV Infection: time to begin again.Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.Combinatorial latency reactivation for HIV-1 subtypes and variantsCombination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1Cell line-dependent variability in HIV activation employing DNMT inhibitorsNovel factors interfering with human immunodeficiency virus-type 1 replication in vivo and in vitro.Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaBThe molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit.Insights into cellular factors that regulate HIV-1 replication in human cellsInteraction between endogenous bacterial flora and latent HIV infection.Histone deacetylase inhibitors and HIV latency.Measuring glutathione redox potential of HIV-1-infected macrophages.Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway.Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.Selective HDAC inhibition for the disruption of latent HIV-1 infection.Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites.The ubiquitin ligase Siah1 controls ELL2 stability and formation of super elongation complexes to modulate gene transcription.HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4)Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradicationThe Environmental Pollutant Cadmium Promotes Influenza Virus Replication in MDCK Cells by Altering Their Redox StateAltering cell death pathways as an approach to cure HIV infection.We all need to know about HIV cure research: a case reportInvestigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS.Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic developmentUnique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cellsTherapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors.HDAC inhibitors in HIV.Small-molecule chromatin-modifying agents: therapeutic applications.Control of HIV latency by epigenetic and non-epigenetic mechanisms.
P2860
Q26781191-3B677165-670D-41C9-9E5A-7A15E84C9A79Q26823236-7AE83D70-0A22-4D9D-A402-710873CE8328Q28468598-222D018C-D98C-43F2-BB0D-49BB817A33FCQ28544949-8BA63886-8666-4D96-8653-151B8262B85DQ30386370-BB6531E5-8E30-409B-BD9D-F9D1EA0A63CCQ30399588-5B7E2895-CE87-48F8-B62E-F19CE043B3BDQ30494064-A8363498-0226-424E-B3CF-746DEE260D50Q33838633-EF122233-AD8B-49F0-85A1-561337063D9CQ33877492-F7B89E5A-8225-4D05-903C-F47672D11181Q34132738-2249BA20-C5C5-4501-B4EF-F7090931F765Q34243934-0D632C78-84DE-40A8-B3C9-13439FA6BDE7Q34323296-2110A094-9978-4D37-9658-5F6B2E591297Q34482017-33EB2D67-88F6-4CC9-A379-3C54580E8713Q34544409-381B5D73-2B71-4E96-835F-2FEAD8E4B97DQ34561070-37006093-4E01-4AE7-A8B2-1F9D922C9C0CQ34686713-C1566B5D-6E8B-4A4A-9FA0-CA2A34BB272DQ34816844-D8C3DFD1-C53E-459D-BAD8-C940E53697E5Q34958392-2F22BD7C-3E2D-4FC9-A548-9A962D51468EQ35016964-0DBB9626-809E-44C7-B21F-0A3173D0C97BQ35113716-8630678A-8DD1-4191-8BE7-BD2AAFF01D64Q35168379-D8D0A454-07C2-4583-9A62-A606EF9E2A67Q35227888-9122644C-50EE-4EBB-82CF-A5854CA1F839Q35436367-E1F70D38-81A9-4C1D-8D64-57ABAEB921E5Q35557244-B70AB999-2F0B-48BB-8C6C-811FFD1C1206Q35990164-CF1D0FA3-A4E3-4BDE-A9C5-EB6F9687EF89Q36121883-55AB059D-0E7D-4BAC-86C6-E793B1305B8BQ36187278-31F4DF32-01B4-4BBF-B3D9-10C3E2BF5EEEQ36330062-20FDD3D1-A4D3-4C3D-BF41-93AD6010AD55Q36656197-FDFD867B-1BAA-494C-B580-13A91889CF17Q37062057-E35EBE1A-BE41-4387-A6A1-8350AAB66835Q37098239-C1173FD8-A314-4EFD-8DFA-8637B03AE3EEQ37109010-B365D5E1-5C90-40D2-A909-400637917DD1Q37127522-8B8DA6FC-5843-4B31-943D-9566A9993CDEQ37388295-A912B308-B33E-4710-889B-6527764286B7Q37626634-C4D9F61C-803C-42C8-AE37-31F302EEB835Q37644561-5089AEF5-48E5-4201-8A6D-029BEB58EFB8Q37855902-B08CA949-1B5C-479F-9CDC-2B1EF9C84D32Q37956178-552BD603-55FA-4F2E-B710-767EDA589783Q37961728-EB0B7EFE-A329-4B50-8608-91D7CAE1172EQ37972643-07588210-95E4-4261-8763-981EC89BB3A5
P2860
"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
"Shock and kill" effects of cl ...... e models for HIV-1 quiescence.
@ast
"Shock and kill" effects of cl ...... e models for HIV-1 quiescence.
@en
type
label
"Shock and kill" effects of cl ...... e models for HIV-1 quiescence.
@ast
"Shock and kill" effects of cl ...... e models for HIV-1 quiescence.
@en
prefLabel
"Shock and kill" effects of cl ...... e models for HIV-1 quiescence.
@ast
"Shock and kill" effects of cl ...... e models for HIV-1 quiescence.
@en
P2093
P2860
P50
P356
P1433
P1476
"Shock and kill" effects of cl ...... e models for HIV-1 quiescence.
@en
P2093
Andrea Savarino
Enrico Garaci
Sandro Norelli
Sary El Daker
P2860
P2888
P356
10.1186/1742-4690-6-52
P577
2009-06-02T00:00:00Z
P5875
P6179
1012743752